The "European Randomized Study of Screening for Prostate Cancer" (ERSPC) was initiated in 1993 and up to 1998 six other European countries were joined.
The main goal is to establish the effect of Prostate Specific Antigen (PSA)-based screening on prostate cancer (PCa) mortality with morbidity as secondary end point. At present, with 11 and 12 years of follow-up significant relative reductions of 21 % and 31 % relating to both end points have been reported. The diagnosis of non-life threatening PCA (over diagnosis) is estimated to be in the range of 50 % and represents the main "harm", which prevents the introduction of population-based screening. As a result, the prevention of over diagnosis is now given top research priority. PSA as a screening test has poor performance characteristics including a low specificity. With the cut-off value of 3.0 ng/ml chosen within ERSPC, about 25 % of men aged 55--69 test positively, 75 % have "negative" test results, which do not definitely exclude the presence of PCa. Research to establish empirical schemes of follow-up based on PSA levels and other parameters are ongoing worldwide. In the meantime, we are, by approximation, capable to identify over diagnosed PCa detected by screening. Active surveillance can be applied to avoid side effects and expenses of treatment and is, among others, based on the grade of differentiation determined on biopsies. The assignment of the most favorable "Gleason score 6" is a crucial decision element. Unfortunately, biopsy pathology underestimates the true degree of PC aggressiveness by 25--30 % which establishes the need of careful follow-up.
Written by:
Schröder FH. Are you the author?
Department of Urology, Erasmus University Medical Center, Room NH-224 3000, 2040, CA, Rotterdam, Netherlands.
Reference: Recent Results Cancer Res. 2014;202:47-51.
doi: 10.1007/978-3-642-45195-9_5
PubMed Abstract
PMID: 24531776
UroToday.com Prostate Cancer Section
